Perspective
BAV-related aortopathy is a common clinical entity. An increasing amount of literature has recently shown that BAV aortopathy is less dangerous than previously described. The current Executive Summary is a condensed version of the ''American Association for Thoracic Surgery Guidelines on Bicuspid Aortic Valve-Related Aortopathy,'' providing clinicians with a current and comprehensive review of BAV aortopathy and its management.
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INTRODUCTION
Bicuspid aortic valve (BAV) disease is the most common congenital cardiac disorder, being present in 1% to 2% of the general population. 1 Associated aortopathy is a common finding in patients with BAV disease, with thoracic aortic dilation noted in approximately 40% of patients in referral centers. Several previous documents have addressed the management of BAV-associated aortopathy, with one of the first being a set of multisocietal guidelines published in 2010. [2] [3] [4] [5] [6] [7] [8] Of these prior publications, none focused entirely on patients with BAV aortopathy. Therefore, the current Consensus Statement differs in that it covers all major aspects of BAV aortopathy, including its natural history, phenotypic expression, histology and molecular pathomechanisms, imaging, indications for surgery, surveillance and follow-up, and recommendations for future research. It aims to provide clinicians with a current and comprehensive review of BAV aortopathy and to guide the daily management of these complex patients. The full Consensus Statement can be found online, and the current document serves as its executive summary (please see full-length document on pages e41-e74 in this issue).
EPIDEMIOLOGY, PATHOPHYSIOLOGY, AND CLINICAL PHENOTYPES
Contemporary clinical outcomes for patients with BAV have been summarized in a comprehensive table by Michelena and colleagues 9 from the International BAV Consortium (see Table 2 in the full-length document on pages e41-e74 in this issue). These data show excellent overall survival of patients with BAV in community, populationbased studies, whereas outcomes are not as good in patients who have required aortic valve replacement (AVR). Heart failure is particularly uncommon in patients with BAV, and aortic stenosis is a more common indication for surgery than aortic insufficiency. Thoracic aortic aneurysm formation (aortic diameter >45 mm) occurs in 25% to 45% of patients over prolonged periods of follow-up. However, aortic dissection is a rare event (1%) outside of tertiary referral center populations, in whom it is more common (10%). 9 The evidence of phenotypic heterogeneity of BAV aortopathy has emerged in the last decade from several observational studies and has stimulated a critical reappraisal of the literature and treatment recommendations. The proposed hypothesis is that different types of BAV aortopathy (ie, so-called aortic phenotypes) may be caused by distinct pathogenetic mechanisms and therefore require individualized surgical approaches. 10, 11 In particular, the 2 longdebated theories on BAV-aortopathy pathogenesis, namely, the genetic and hemodynamic theories, could both be plausible inasmuch as different phenotypic forms might be variable expressions of both causative factors. Phenotypic heterogeneity of BAV aortopathy also may explain some of the inconsistencies in published natural history and follow-up studies, especially regarding the risk of aortic events in BAV disease. Previous data from mixed BAV cohorts resulted in a wide variety of suggested surgical treatments, ranging from very conservative approaches to very aggressive recommendations, usually extrapolated from guidelines for management of patients connective tissue disorders (eg, Marfan syndrome). 3 Clinicians' thresholds for surgical intervention of BAV-associated aortopathy have been similarly diverse and sometimes inconsistent with consensus opinion and guidelines. 12 
AORTIC IMAGING
Transthoracic echocardiography (TTE) is the recommended imaging modality for the initial assessment of the aortic valve and thoracic aorta, including the assessment of hemodynamic aortic valve function 13 (Table 1) . If any part of the aorta is dilated or complete examination of the aorta is not possible by TTE, computed tomography (CT) or magnetic resonance imaging (MRI) is recommended. Hemodynamic aortic valve assessment also can be performed by MRI, although TTE remains the gold standard. TTE assessment of aortic valve function is usually sufficient, but transesophageal echocardiography should be performed in patients with unexplained left ventricular dilation or dysfunction. When evaluating the BAV aorta with echocardiography, the entire thoracic aorta should be assessed: aortic root (aortic annulus, sinuses of Valsalva and sinotubular junction), tubular ascending aorta (proximal, mid, and distal), aortic arch, and descending thoracic aorta, including diameter and Doppler assessment for the presence of coarctation.
Echocardiography-derived aortic root diameters greater than 40 mm should be verified by electrocardiogramgated CT or MRI ( Table 1 ). Given that the sinuses can dilate asymmetrically, all 3 sinus-to-commissure (or sinus-tosinus) dimensions should be measured. 14 The choice between CT and MRI is dependent on their availability, the institutional expertise, and the age of the patient. Younger patients (ie, aged <50 years) would benefit from MRI surveillance to avoid CT-associated radiation exposure. Ideally, interval measurements should be performed with the same imaging modality and same technique (ie, electrocardiogram-gated), and compared side-by-side by an experienced reader. 13 
Aortic Imaging Surveillance
In patients with initial aortic dilatation (root or tubular ascending aorta 40-49 mm), the thoracic aorta should be reimaged at 12 months. If stability is confirmed, then reimaging can be performed every 2 or 3 years ( Table 2 ). The first interval repeat measurement may be performed at 6 months before proceeding to yearly assessments, especially if other risk factors such as aortic coarctation or family history of dissection are present. In patients with more advanced initial aortic dilatation (root or tubular ascending aorta 50-54 mm), the thoracic aorta should be reimaged at least every 12 months (yearly). As opposed to Marfan syndrome in which the aortic root is predominantly involved, the most common segment involved in patients with BAV is the tubular ascending aorta 9 (60%-70% of BAV dilated aortas). Aortic growth rates for the tubular ascending segment in adults with BAV have recently been reported to range from 0.4 to 0.6 mm/y, 15, 16 whereas earlier studies demonstrated maximal dilatation rates of 1 to 2 mm/y. Few patients are observed to have a dilation rate greater than 2 mm/y 15, 16 Although these represent ''artificially annualized'' rates, it remains unlikely that patients with BAV will dilate at more than 3 mm/y. It is also important to note that an interval diameter change of 1 or 2 mm is within the margin of error by current imaging modalities. Therefore, an interval dilatation of 3 mm or greater should be considered clinically significant. 6 Absolute echocardiographic baseline aorta diameters do not reliably predict the rate of dilatation; thus, systematic interval imaging follow-up is required regardless of baseline diameter. Previous AVR is more common in patients with BAV presenting with aortic dissection, compared with patients with tricuspid aortic valve (TAV) with dissection. 17 Therefore, continued interval monitoring of the unrepaired aorta post-AVR is suggested when there is evidence of aortopathy by surgical or radiologic examination.
SURGICAL MANAGEMENT
The most important clinical decision for patients with BAV-associated aortopathy is the appropriate timing of surgical intervention. Optimally, surgery should be recommended as soon as the risk of watchful waiting exceeds the risk of surgical intervention. Unfortunately, the precise time point when this occurs is sometimes difficult to identify because it is dependent on the individual patient, surgeon, and treatment center. Prophylactic aortic repair is recommended to prevent catastrophic aortic complications, that is, aortic dissection and rupture. Factors that should be considered when recommending aortic repair include maximum aortic diameter, presence of aortic risk factors (ie, rate of aortic growth, aortic wall thickness, BAV phenotype, uncontrolled hypertension, family history of aortic complications, or other aortic conditions such as coarctation or connective tissue disorders), presence of surgical risk factors (eg, advanced age, decreased left ventricular function, redo surgery), concomitant indications for cardiac surgery (most commonly aortic valvular stenosis or insufficiency), and surgeon/team experience and expertise.
Indications for Aortic Repair in Patients With Bicuspid Aortic Valve With Significant Aortic Valve Dysfunction
For patients with BAV and valve dysfunction significant enough to meet indications for aortic valve surgery, concomitant ascending aortic replacement is reasonable when the diameter exceeds 4.5 cm (Class IIa, level of evidence C in American Heart Association (AHA)/American College of Cardiology (ACC) 2014 guidelines, 4 European Society of Cardiology (ESC) 2014 aortic guidelines, 6 ESC valvular guidelines 7 ) ( Table 3 ). The incidence of aortic dissection and other aortic catastrophes post-AVR is low, particularly in patients with BAV with aortic stenosis. 19, 22 Most patients with BAV undergoing AVR do not require complete aortic root replacement surgery. Indeed, the incidence of aortic root dilation post-AVR in patients with BAV is low, similar to the incidence in patients with TAV disease. [23] [24] [25] Root replacement is reasonable to consider in patients with BAV undergoing AVR with an aortic root diameter exceeding 4.5 cm.
The type of implanted valve at the time of AVR may influence the extent of aortic repair in patients with BAV. In patients with moderate aortic root dilation who have opted for a mechanical valve, complete root replacement may be considered. However, isolated AVR is preferable in young patients who have opted for a biological valve because of the low risk of subsequent aortic root rupture/dissection 23, 25 and the increased technical difficulty associated with repeat aortic root replacement surgery. 26 Patients with bicuspid aortopathy and relatively normal aortic cusps with good mobility can be considered for valve-sparing aortic root replacement surgery (ie, David operation) in select centers (Table 3) . Valve-sparing aortic root replacement in patients with BAV is technically challenging and should be performed by surgeons with substantial clinical experience in TAV patients. Aortic valve repair has been applied in carefully selected patients with BAV. Good midterm results for isolated aortic valve repair have been demonstrated in expert hands. 27, 28 However, the lack of long-term follow-up data and the increased technical complexity of aortic valve repair in patients with BAV have resulted in a lack of widespread adoption of these techniques.
Indications for Aortic Repair in Patients With Bicuspid Aortic Valve Without Significant Aortic Valve Dysfunction
Current guidelines recommend intervention on the aorta in patients with BAV without significant aortic valvular dysfunction (ie, valvular dysfunction does not meet criteria for surgical valve repair/replacement) if the maximal aortic diameter exceeds 5.5 cm and patients do not have any highrisk characteristics (Table 3) In patients with normal initial aortic diameters by TTE, the thoracic aorta should be reimaged every 3 to 5 y.
I/C 13, 15 In patients with initial aortic dilatation (root or tubular ascending aorta measure 40-49 mm), the thoracic aorta should be reimaged at 12 mo. If stability is confirmed, then reimaging can be performed every 2 or 3 y.
I/C 6, 13, 15, 16 In patients with more advanced initial aortic dilatation (root or tubular ascending aorta 50-54 mm), the thoracic aorta should be reimaged at least every 12 mo (yearly).
I/C 20 it is unknown at what aortic diameter these dissections tend to occur. It is also unknown whether a dilated BAV aorta is at greater risk than a dilated TAV aorta. Further complicating the issue, it has been observed that many patients with aortic dissection present with an aortic diameter of less than 5.5 cm. 29, 30 Despite this finding, routine replacement of the ascending aorta in patients with an aortic diameter of less than 5.5 cm is not warranted because the size of the denominator is not known (ie, ''aortic size paradox'').
Certain factors may increase the risk of aortic complications in patients with BAV and therefore lead to an earlier recommendation for intervention. Current guidelines recommend surgical intervention at an aortic diameter of 5.0 cm in patients with any of the following risk factors: aortic coarctation, a family history of aortic dissection, or rapid aortic growth (>3-5 mm/y). In the AHA/ACC 2014 valvular guidelines, this is a Class IIa, level of evidence C recommendation, 4 and in the ESC 2014 aortic guidelines, this is a Class I, level C recommendation. 6 Intervention at lower aortic diameters also can be considered in patients with small body surface area or stature, particularly if they have Turner syndrome. An indexed aortic diameter cutoff of greater than 2.75 cm/m 231 or an aortic crosssectional area to height ratio of greater than 10 cm/m 232 may be used to guide earlier surgical intervention in patients with small stature. Earlier intervention is occasionally justified in patients with a strong preference for early surgery. Finally, surgical repair may be performed at a lower threshold (ie, 5.0 cm) if the patient has low operative risk and the procedure is performed by an experienced operative team with established results. 2, 3, 32, 33 These recommendations generally reflect a change toward a more conservative approach for BAV-associated aortopathy when compared with previous guidelines, which stated that such patients should be managed as aggressively as those with connective tissue disorders. 3 Studies published subsequent to these earlier guidelines have demonstrated that patients with BAV have a markedly lower risk of aortic complication and aortic dilation than those with Marfan syndrome, with aortic catastrophe rates that are similar to rates in patients with TAV aneurysm. 15, 20, 34, 35 It is possible that some patients with BAV with distinct morphologic patterns of dilatation are at increased risk for complications. A recent joint statement of clarification was published to address the discrepancies in previously published guidelines. 8 
Management of Aortic Arch
BAV disease and associated aortopathy have been the topics of multiple guidelines and consensus statements, but most do not address the aortic arch specifically. Neither the 2010 ACC/AHA guidelines 3 nor the ESC Guidelines 6 discuss indications for aortic arch repair in patients with BAV. The 2014 Canadian Cardiovascular Society Position statement was the first to recommend a threshold of 5.5 cm for replacement of aortic arch aneurysm associated with BAV. 36 Indications for repair of the aortic arch should be no different in the setting of BAV compared with TAV. If a patient with BAV presents for AVR and has an ascending aortic aneurysm with a normal aortic diameter at the takeoff of the innominate artery, ascending aortic repair without arch intervention is recommended. If the aortic arch has a diameter of greater than 45 mm at the innominate artery takeoff, hemiarch replacement is reasonable in experienced centers, with the understanding that operative mortality and risk of stroke may be increased. Total arch replacement is reasonable in patients with BAV undergoing AVR with a mid-aortic arch diameter of 4.5 cm or greater as measured orthogonally by volume-rendered, cross-sectional imaging reconstructions. However, such pathology is rare and usually found in patients with BAV with other causes of aortic arch dilation (eg, previous aortic coarctation repair or aortic dissection, concomitant connective tissue disorder, Turner syndrome). Patients with BAV requiring complex elective aortic arch surgery should be referred to high-volume centers with established results.
37,38
MEDICAL MANAGEMENT Follow-up Aortic Imaging
Imaging of the aorta early after surgical correction is aimed at detecting anastomotic leaks and pseudoaneurysms, as well as establishing a baseline for future comparisons. Electrocardiogram-gated cardiac CT may be preferred to nongated CT angiography or TTE for early postoperative surveillance, because echocardiography is often limited by the presence of prosthetic aortic valves and therefore may miss periannular or anastomotic dehiscence. In younger individuals (aged <50 years), however, repeat CT examinations should be used with caution to avoid the risk of radiation-induced malignancy. In such instances, MRI is preferable.
The interval at which repeat imaging is performed after aortic surgery is often dictated by the extent of the initial operation and whether areas of aortic dilatation were not addressed during the initial surgery. In the absence of residual aortic dilation/pathology, it is reasonable to suggest that the entire aorta be imaged by CT or MRI 1 year after replacement and then as directed by clinical circumstances or evidence of aortic dilatation/pathology from that point forward (Table 4 ). When possible, these studies should be performed at the same institution using similar imaging techniques and protocols to minimize variation.
Medical Management and Watchful Waiting
The medical management of patients with BAV aortopathy who are under surveillance consists mainly of blood pressure control, along with cardiovascular risk reduction via pharmacologic and nonpharmacologic measures. There are no randomized trials to help guide decision making in this specific patient group. Treating hypertension with beta-blockers or inhibitors of the renin-angiotensin system has been suggested, however, based largely on extrapolation from studies in the Marfan syndrome literature. 36, 46 At the present time, there are no data to support lower blood pressure thresholds for patients with dilated aortas in the setting of BAV, and therefore, country-and region-specific guidelines for treatment of hypertension should be followed. General counseling on nonpharmacologic approaches to cardiovascular risk reduction should be part of watchful waiting in patients with BAV aortopathy.
There are no specific recommendations regarding automobile driving in patients with BAV aortopathy in previously published guidelines. However, the Canadian Medical Association has recommended that patients with abdominal aortic aneurysm be precluded from driving when the rupture risk exceeds 10% per year. 36 On the basis of the best available observational data, this threshold of risk is exceeded for thoracic aortic aneurysms greater than 6.0 cm in the ascending aorta or arch and greater than 6.5 cm in the descending aorta. A lower threshold for rupture risk is reasonable for patients performing commercial driving. 36, 47 Exercise prescription or restrictions should be individualized in patients with aortic aneurysms. Patients with previously repaired aortic dissection should avoid strenuous lifting, pushing, or straining that would require a Valsalva maneuver. 3, 36, 48, 49 Strenuous strength training may be dangerous for patients with BAV aortopathy, because aortic dissection has been linked to weight lifting. 49 The proposed mechanism is transiently elevated blood pressure associated with isometric exercise or Valsalva maneuver. 48 Heavy weight lifting or competitive athletics involving isometric exercise may trigger aortic dissection, and such activities should be avoided in patients with moderately dilated aortas (ie, >45 mm) or when there has been a significant interval increase in size. However, individuals with bicuspid aortopathy can (and should) undergo aerobic or endurance exercise because these exercises are beneficial for blood pressure lowering. 50 If patients want to engage in vigorous aerobic exercise, one might consider performing a symptom-limited stress test to ensure that the patient does not have a hypertensive response to exercise. In patients with a normal bicuspid valve and no associated dilated aorta, no exercise restrictions are required. Patients with BAV and dilated aorta should be precluded from private driving if the ascending aorta diameter is >6.0 and restricted from commercial driving if the ascending thoracic aorta diameter is >5.5 cm.
IIa/C 36, 47 It is recommended that prepregnancy evaluation and postpregnancy management of women with BAV with or without associated aortopathy be performed by practitioners with expertise in the management of pregnant women with heart disease.
I/C 59
First-degree relatives of patients with BAV should undergo screening echocardiography.
IIa/B 52 LOE, Level of evidence; CTA, computed tomography angiography; MRA, magnetic resonance angiography; CT, computed tomography; MRI, magnetic resonance imaging; BAV, bicuspid aortic valve.
Family Screening
Most cases of BAV disease are sporadic, but familial clustering is not uncommon. Genetic studies have suggested an autosomal dominant pattern with incomplete penetrance and variable expressivity as the likely mode of inheritance. 51 Approximately 10% of first-degree relatives have the disorder. 52 Therefore, it is recommended that firstdegree relatives of patients with BAV are screened with echocardiography.
CONCLUSIONS
BAV disease with associated aortopathy is a complex condition with elusive genetics and controversial pathophysiology. By virtue of the high frequency of BAV disease in the general population, cardiac specialists should be familiar with current recommendations for assessment, monitoring, and treatment of this disorder.
The current document is an executive summary of a larger consensus statement that covers all major aspects of BAV aortopathy, including its natural history, phenotypic expression, histology and molecular pathomechanisms, imaging, indications for surgery, surveillance, and follow-up, and recommendations for future research (please see fulllength document on pages e41-e74 in this issue). Detailed recommendations are found in Tables 1 to 4 accompanying this executive summary, which are meant to serve as a guide to assist clinicians with the daily management of these complex patients.
